Table 6.
Geometric Mean Serum Neuraminidase-Inhibition Antibody Titer and Mean Fold Increase of Healthy Adults to 2008–2009 Influenza Vaccines1
| Vaccine | A/Brisbane/59/07 (N1) | A/Brisbane/10/07 (N2) | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Pre | Post | Fold Increase | Pre | Post | Fold Increase | |
| Afluria | 7.52 | 8.78 | 1.26 | 7.76 | 8.90 | 1.14 |
| Fluarix | 7.35 | 8.02 | 0.66 | 7.31 | 9.35 | 2.04 |
| Flulaval | 7.45 | 8.06 | 0.61 | 7.36 | 9.07 | 1.71 |
| Fluzone | 7.92 | 8.95 | 1.02 | 7.89 | 9.14 | 1.25 |
| Fluvirin | 7.77 | 8.80 | 1.02 | 7.26 | 8.91 | 1.65 |
| Flumist | 7.66 | 8.13 | 0.47 | 7.77 | 7.94 | 0.17 |
1
GMT – log2
2
N=30 in each group
Comparisons: Anova for differences between vaccines, pre = NS for N1 and N2, post p=.051 for N1 and <.001 for N2, fold increase p=.019 for N1 and < .001 for N2. Duncan’s post hoc for differences among vaccines; the fold increase for N1 was greater for Afluria than for Flumist, Fluarix and Flulaval. Fluarix was greater than Afluria, Fluzone and Flumist for N2.